Global Celiac Disease Diagnostics Market Poised for Remarkable Growth

Celiac.com 05/14/2024 - The global celiac disease diagnostics market is set to witness substantial expansion, with projections indicating a value of US$ 647.3 million by 2033, with an anticipated Compound Annual Growth Rate (CAGR) of 8.3%. This forecast represents a significant increase from its value of nearly US$ 292.8 million in 2023.

Celiac disease is an autoimmune condition triggered by gluten consumption that affects millions worldwide. As awareness surrounding this ailment increases and its prevalence escalates, there is a growing demand for advanced diagnostic solutions. Technological innovations in diagnostic tests are further propelling market growth by facilitating more precise and timely detection of celiac disease.

Celiac.com Sponsor (A12):
People with celiac disease suffer adverse reactions to gluten, a protein commonly found in wheat, rye, and barley. Untreated celiac disease can lead to severe complications such as malnutrition and an increased risk of certain cancers.

The increasing prevalence of celiac disease underscores the urgent need for enhanced diagnostic capabilities. The global market for celiac disease diagnostics is well-positioned to meet this demand by providing innovative solutions for the early detection and management of the condition.

Key projections include North America maintaining its status as the largest market for celiac disease diagnostics, with the celiac disease serology tests segment expected to hold the largest market share in 2023. However, the molecular diagnostics segment is expected to experience the fastest CAGR during the forecast period.

Driving factors behind the market's growth include the rising awareness of celiac disease, attributed to public awareness campaigns by celiac disease organizations and the increasing availability of gluten-free foods. Moreover, the prevalence of celiac disease is estimated to be around 1% of the global population, with the potential for even higher rates due to various factors such as genetic predisposition and increased gluten consumption.

Furthermore, the market is benefiting from the expanding array of diagnostic tests available for celiac disease. While blood tests for gluten antibodies remain the most common, there is a growing development of non-invasive tests such as genetic and stool testing, aiming to simplify and broaden the accessibility of celiac disease diagnosis.

Read more at fmiblog.com